Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- Check5 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoChange DetectedMinor edits to the Publications section note clarifying that publications are provided voluntarily by the person entering information about the study and pertain to the results. A new Revision: v3.3.1 was added; the previous version was v3.2.0.SummaryDifference0.1%

- Check20 days agoChange DetectedNotice about government funding and NIH Clinical Center operating status was removed from the page. All study details and trial information remain unchanged.SummaryDifference0.4%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedAdded a Study Results section and a Publications entry (Biomarker Research 2022) for pembrolizumab activity in Fanconi anemia pathway tumors on the Study Details page.SummaryDifference0.5%

- Check62 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference4%

- Check70 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive changes.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.